Fordel StudiosOpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation
What Happened
Chai is building foundation models for drug discovery, specifically to predict interactions between molecules so they could be reprogramed for cures.
Our Take
This one actually stacks up. Drug discovery is a real bottleneck with unit economics that work: if you can genuinely speed up molecular interaction prediction, pharma companies will pay for it. Foundation models for molecules make sense because the problem is fundamentally about pattern recognition at scale.
Unlike consumer AI, biotech AI has defensibility (data + regulatory moat) and clear ROI. You're not fighting virality - you're solving a $200B problem. That's why the valuation makes sense.
What To Do
Biotech AI is the one category where high valuations actually track real bottleneck-solving; everything else is still speculative.
Cited By
React